Larsson Anders, Ronquist Gunnar, Wülfing Christian, Eltze Elke, Bettendorf Olaf, Carlsson Lena, Nilsson B Ove, Semjonow Axel
Department of Medical Sciences, Clinical Chemistry, University Hospital, Uppsala, Uppsala, Sweden.
Urol Oncol. 2006 May-Jun;24(3):195-200. doi: 10.1016/j.urolonc.2005.07.009.
Prostasomes are secretory granules synthesized, stored, and secreted by normal and neoplastic human prostate epithelial cells. In prostate cancer, they are anticipated to be released into the blood circulation where they may be immunogenic. The aim of our study was to examine whether prostasome antibody presence in serum bears any prognostic significance for men with prostate cancer. We developed a sensitive and specific immunoassay (enzyme-linked immunosorbent assay) to establish the presence of antiprostasome antibodies in serum. The antiprostasome antibody titer in serum, sampled before any kind of therapy for prostate cancer, was examined together with clinicopathologic variables and outcome over a median follow-up of 350 days in 218 patients with verified prostate cancer. We detected these antibodies in 191 (88%) of these patients. This antibody titer did not correlate to serum values of prostate-specific antigen. Significant, inverse relationships were registered for antiprostasome antibody titer, and metastases to bone and/or lymph nodes (P = 0.035) and pT (P = 0.025). These results indicate that the antiprostasome antibody titer in serum may be a novel marker for prostate cancer liability to metastasize.
前列腺小体是由正常和肿瘤性人前列腺上皮细胞合成、储存和分泌的分泌颗粒。在前列腺癌中，预计它们会释放到血液循环中，在那里它们可能具有免疫原性。我们研究的目的是检查血清中前列腺小体抗体的存在对前列腺癌男性患者是否具有任何预后意义。我们开发了一种灵敏且特异的免疫测定法（酶联免疫吸附测定法）来确定血清中抗前列腺小体抗体的存在。在218例经证实的前列腺癌患者中，对在任何前列腺癌治疗之前采集的血清中的抗前列腺小体抗体滴度进行了检测，并将其与临床病理变量及在中位随访350天期间的预后情况进行了对比。我们在这些患者中的191例（88%）中检测到了这些抗体。这种抗体滴度与前列腺特异性抗原的血清值无关。抗前列腺小体抗体滴度与骨和/或淋巴结转移（P = 0.035）以及pT（P = 0.025）之间存在显著的负相关关系。这些结果表明，血清中的抗前列腺小体抗体滴度可能是前列腺癌转移倾向的一种新标志物。
